HCP Live: The Significance of DAPA-HF for Cardiovascular Care and Beyond

June 11, 2021

To say that SGLT-2 inhibitor dapagliflozin has made great strides in cardiovascular care is an understatement.

Data has supported the drug’s ability to provide glycemic benefit among patients with diabetes, and recent trials have only bolstered its promise in improving cardiometabolic, cardiovascular, and renal outcome

HCP Live talked to Dr. Mikhail Kosiborod, director of Cardiometabolic Research at Saint Luke's Mid America Heart Institute and vice president of research at Saint Luke's Health System, about the clinical impact of the DAPA-HF trial. 

Read the full HCP Live article: The Significance of DAPA-HF for Cardiovascular Care and Beyond

Related Content

DARE-19 Phase III trial did not reach statistical significance for primary endpoints, but showed numerically fewer events of new or worsened organ dysfunction or death in patients hospitalized with COVID-19
Saint Luke's Mid America Heart Institute shared detailed trial results in a Late Breaking Clinical Trials Session at the American College of Cardiology Scientific Session.
HCP Live: Heart Trials Podcast: DAPA-HF, with Mikhail Kosiborod, MD
Dr. Mikhail Kosiborod discusses the DAPA-HF trial, as well as the DARE-19 trial results, in this episode of HCP Live's Heart Trials podcast.
Saint Luke’s Researchers Again Take Center Stage at Global Cardiology Conference
Saint Luke’s Mid America Heart Institute to share detailed trial results at American College of Cardiology Scientific Session May 15-17.